Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX7 | Q99572 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 1/20 | 0.39 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.39 |
| ▸ | WNT3A | P56704 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 1/20 | 0.38 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | CDC7 | O00311 | 2/20 | 0.36 |
| ▸ | DBF4 | Q9UBU7 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.35 |
| ▸ | GABRP | O00591 | 1/20 | 0.35 |
| ▸ | GABRD | O14764 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.35 |
| ▸ | GABRB1 | P18505 | 1/20 | 0.35 |
| ▸ | GABRG2 | P18507 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3567261 | 0.84 | P2RX7 (0.45) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL11531412 | 0.82 | P2RX7 (0.44) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL3401108 | 0.82 | P2RX7 (0.44) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL1380026 | 0.78 | KMT2A (0.45) | NAMPTKMT2ACDC7DBF4MEN1 | |
| SCHEMBL29508230 | 0.78 | CYP1A2 (0.53) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL917137 | 0.78 | CYP1A2 (0.53) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL5558104 | 0.78 | P2RX7 (0.47) | P2RX7FAAHCTNNB1WNT3AGRM4 | |
| Hydrochloric Acid SCHEMBL4763043 | 0.77 | KMT2A (0.44) | NAMPTKMT2ACDC7DBF4MEN1 | |
| Hydrochloric Acid SCHEMBL27922723 | 0.76 | CYP1A2 (0.51) | P2RX7FAAHCTNNB1WNT3ANAMPT | |
| SCHEMBL27498088 | 0.75 | P2RX7 (0.49) | P2RX7FAAHCTNNB1WNT3ANAMPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-4805809-B2 | — | — | 2011-11-02 | — | — | JP | claimed |
| EP-1603876-B1 | PROCESS FOR THE PREPARATION OF PYRIDINYL AND PYRIMIDINYL MONO-FLUORINATED BETA KETO ESTERS | SANOFI AVENTIS (FR) | 2007-02-14 | — | — | EP | claimed |
| US-7135569-B2 | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters | SANOF I-AVENTIS (FR) | 2006-11-14 | — | — | US | claimed |
| JP-2006519815-A | — | — | 2006-08-31 | — | — | JP | claimed |
| US-20060058526-A1 | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters | SANOFI-AVENTIS (FR) | 2006-03-16 | — | — | US | claimed |
| EP-1603876-A1 | PROCESS FOR THE PREPARATION OF PYRIDINYL AND PYRIMIDINYL MONO-FLUORINATED BETA KETO ESTERS | Sanofi-Aventis (FR) | 2005-12-14 | — | — | EP | claimed |
| WO-2004078725-A1 | PROCESS FOR THE PREPARATION OF PYRIDINYL AND PYRIMIDINYL MONO-FLUORINATED BETA KETO ESTERS | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | WO | claimed |
| EP-1454900-A1 | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters | SANOFI-SYNTHELABO (FR) | 2004-09-08 | — | — | EP | claimed |
| EP-1603876-B1 | PROCESS FOR THE PREPARATION OF PYRIDINYL AND PYRIMIDINYL MONO-FLUORINATED BETA KETO ESTERS | SANOFI AVENTIS (FR) | 2007-02-14 | — | — | EP | disclosed |
| US-7135569-B2 | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters | SANOF I-AVENTIS (FR) | 2006-11-14 | — | — | US | disclosed |
| US-20060058526-A1 | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters | SANOFI-AVENTIS (FR) | 2006-03-16 | — | — | US | disclosed |
| EP-1603876-A1 | PROCESS FOR THE PREPARATION OF PYRIDINYL AND PYRIMIDINYL MONO-FLUORINATED BETA KETO ESTERS | Sanofi-Aventis (FR) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004078725-A1 | PROCESS FOR THE PREPARATION OF PYRIDINYL AND PYRIMIDINYL MONO-FLUORINATED BETA KETO ESTERS | SANOFI-AVENTIS (FR) | 2004-09-16 | — | — | WO | disclosed |
| EP-1454900-A1 | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters | SANOFI-SYNTHELABO (FR) | 2004-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060058526-A1 | Process for the preparation of pyridinyl and pyrimidinyl mono-fluorinated beta keto-esters | KHK, AKR1C3, AKR1C4 | P2RX7 2878/4885FAAH 699/4885CTNNB1 1342/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.